TY - JOUR T1 - Peptide-Based Probes for Cancer Imaging JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 1735 LP - 1738 DO - 10.2967/jnumed.108.053041 VL - 49 IS - 11 AU - Jean Claude Reubi AU - Helmut R. Maecke Y1 - 2008/11/01 UR - http://jnm.snmjournals.org/content/49/11/1735.abstract N2 - Receptors for regulatory peptides are overexpressed in a variety of human cancers. They represent the molecular basis for in vivo imaging with radiolabeled peptide probes. Somatostatin-derived tracers, designed to image the sst2-overexpressing neuroendocrine tumors, have enjoyed almost 2 decades of successful development and extensive clinical applications. More recent developments include second- and third-generation somatostatin analogs, with a broader receptor subtype profile or with antagonistic properties. Emerging tracers for other peptide receptors, including cholecystokinin/gastrin and GLP-1 analogs for neuroendocrine tumors, bombesin and neuropeptide-Y analogs for prostate or breast cancers, or Arg-Gly-Asp peptides for neoangiogenesis labeling, are also in current development. Application fields include both SPECT/CT and PET/CT. ER -